Unilever Foundry (18 May 2021) - Problem Statement (3)
Green transport platform to implement shared resources, minimise empty transport legs & protect our planet.
For early-stage startups with robust solutions & readiness to grow with Unilever.
Green transport platform to implement shared resources, minimise empty transport legs & protect our planet.
For early-stage startups with robust solutions & readiness to grow with Unilever.
Solutions that consider customer demands that may change rapidly (such as delivery destination, delivery window) to improve logistics efficiency.
For early-stage startups with robust solutions & readiness to grow with Unilever.
A platform to synchronise different transportation, yard & warehousing systems to optimise resources & unlock efficiency with speed.
For early-stage startups with robust solutions & readiness to grow with Unilever.
Objective:
Desired Outcomes:
Current Limitations:
Objective:
Desired Outcomes:
Current Limitations:
Objectives:
Desired Outcomes:
Current Limitation:
About the Problem Statement:
One of the future growth pillars for Mitsubishi Chemical Holdings Corporation’s (MCHC) healthcare business is to provide ‘around the pill solutions’ enabled by digital technology, intended to improve the quality of life of patients and their families, in their core therapeutics areas. Therapeutics areas of interest include the central nervous system (especially neuromuscular disease), autoimmune diseases and metabolic diseases.
Objectives:
To establish multiple touchpoints with patients during the patient journey from prevention to prognosis, to collect and analyse healthcare data and expand the value of current treatments.
Examples of such solutions could be digital platforms enabling patient-centric disease management, electronic patient-reported outcomes, digital diagnostics, disease tracking, digital medication management, digital biomarker, etc.
Working Model:
MCHC is open to strategic investments as well as partnership opportunities with digital health startups in Asia Pacific who have their product ready for a feasibility study.
Automatic 3-way invoice match against shipment information & rate cards, for air/ocean freight & customs brokerage/trucking operations.
Open to providing relevant startups with data sets & more information.
To automate this highly manual process & improve the standardisation & visibility of the booking process.
Open to providing relevant startups with data sets & more information.
About the Problem Statement:
Teijin Pharma Limited (Teijin) is looking for solutions to treat neurological diseases in the Japanese population.
Hardware MedTech startups for neuromodulation and software startups experience in healthcare for a mobile app would be relevant.
Objectives:
To save and reduce patients with neurological diseases relating to the central nervous system, including psychiatric and neurodegenerative diseases. Solution examples include user-friendly therapeutic modalities like non-invasive neuromodulation and/or digital therapeutics at home.
Working Model:
Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.
To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).